Eli Lilly Launches Discounted Zepbound Weight Loss Drug

Eli Lilly has launched a new form of its weight loss drug Zepbound in vial form, significantly reducing prices to $399 and $549 per month for the 2.5-milligram and 5-milligram doses, respectively. This initiative aims to enhance access for uninsured patients, particularly those on Medicare, amidst rising demand for obesity medications. By selling directly through its website, Lilly seeks to combat counterfeit issues and streamline distribution, while also increasing manufacturing capabilities. Analysts suggest this move could shift market share away from compounded medications and rival companies like Novo Nordisk, which continues to face shortages. The company's strategy has been to alleviate supply bottlenecks associated with traditional auto-injector pens. Lilly's proactive pricing strategy is expected to positively impact patient access and help meet the growing need for effective weight loss treatments.